Open Access iconOpen Access

VIEWPOINT

crossmark

AAV-based gene therapy approaches for genetic forms of tauopathies and related neurogenetic disorders

MOHAMED AGHYAD AL KABBANI1,2, GILBERT WUNDERLICH3,4, CHRISTOPH KöHLER5, HANS ZEMPEL1,2,*

1 Faculty of Medicine and University Hospital Cologne, Institute of Human Genetics, University of Cologne, Cologne, 50931, Germany
2 Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, 50931, Germany
3 Faculty of Medicine and University Hospital Cologne, Department of Neurology, University of Cologne, Cologne, 50937, Germany
4 Faculty of Medicine and University Hospital Cologne, Center for Rare Diseases, University of Cologne, Cologne, 50937, Germany
5 Faculty of Medicine and University Hospital Cologne, Center Anatomy, Department of Molecular and Translational Neuroscience, University of Cologne, Cologne, 50931, Germany

* Corresponding Author:HANS ZEMPEL. Email: email

BIOCELL 2022, 46(4), 847-853. https://doi.org/10.32604/biocell.2022.018144

Abstract

Tauopathies comprise a spectrum of genetic and sporadic neurodegenerative diseases mainly characterized by the presence of hyperphosphorylated TAU protein aggregations in neurons or glia. Gene therapy, in particular adeno-associated virus (AAV)-based, is an effective medical approach for difficult-to-treat genetic diseases for which there are no convincing traditional therapies, such as tauopathies. Employing AAV-based gene therapy to treat, in particular, genetic tauopathies has many potential therapeutic benefits, but also drawbacks which need to be addressed in order to successfully and efficiently adapt this still unconventional therapy for the various types of tauopathies. In this Viewpoint, we briefly introduce some potentially treatable tauopathies, classify them according to their etiology, and discuss the potential advantages and possible problems of AAV-based gene therapy. Finally, we outline a future vision for the application of this promising therapeutic approach for genetic and sporadic tauopathies.

Keywords


Cite This Article

AL KABBANI, M.A., WUNDERLICH, G., KöHLER, C., ZEMPEL, H. (2022). AAV-based gene therapy approaches for genetic forms of tauopathies and related neurogenetic disorders. BIOCELL, 46(4), 847–853.



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1727

    View

  • 772

    Download

  • 0

    Like

Share Link